GlassScriptPhysician profile
Wentong Pan
NPI 1952624025
$10,569.52
in general payments reported to CMS, 2019-2025
42 companies · $3,382 in 2025
The $3,382 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $434 · 2021: $256 · 2022: $884 · 2023: $2,016 · 2024: $2,978 · 2025: $3,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,346 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,346.24 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,530.23 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Dexcom, INC. | $1,052.25 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Lilly USA, LLC | $1,044.69 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $546.35 | 2019-2025 | |
| Corcept Therapeutics | $508.56 | 2022-2025 | Korlym |
| Amgen INC. | $506.09 | 2019-2025 | Prolia, Evenity, Tepezza |
| Medtronic, INC. | $472.83 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Insulet Corporation | $449.04 | 2019-2025 | Omnipod |
| Beta Bionics, INC. | $417.24 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $414.03 | 2024-2025 | |
| Abbott Laboratories | $389.79 | 2022-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Neurocrine Biosciences, INC. | $350.78 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $298.14 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Madrigal Pharmaceuticals | $295.82 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.50 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $210.65 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Cequr Corporation | $187.71 | 2024-2025 | Cequr Simplicity |
| Astellas Pharma US INC | $166.86 | 2024 | Veozah |
| Alexion Pharmaceuticals, INC. | $152.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $148.33 | 2019-2023 | Farxiga |
| Ascendis Pharma Endocrinology INC | $147.35 | 2025 | Yorvipath |
| Abbvie INC. | $114.75 | 2019-2025 | |
| Embecta Corp. | $114.73 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Boston Scientific Corporation | $111.76 | 2024 | |
| Pfizer INC. | $110.52 | 2019-2022 | |
| Kyowa Kirin, INC. | $97.96 | 2024-2025 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $78.09 | 2019-2023 | |
| Mannkind Corporation | $75.81 | 2022-2025 | Afrezza |
| Recordati_rare_diseases_inc. | $64.27 | 2023-2024 | Isturisa, Signifor Lar |
| Sequel Med Tech, LLC | $50.01 | 2025 | Twiist |
| Opko Pharmaceuticals, LLC | $30.86 | 2024 | Rayaldee |
| Antares Pharma, INC. | $22.03 | 2023 | Nocdurna, Xyosted, Tlando |
| Novartis Pharmaceuticals Corporation | $21.65 | 2025 | |
| Becton, Dickinson and Company | $18.07 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.27 | 2025 | Jynarque |
| Radius Health, INC. | $16.30 | 2019 | |
| Halozyme INC | $15.76 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.20 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.89 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.99 | 2019 | |
| Ibsa Pharma INC. | $12.03 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wentong Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.